跳至主要内容
临床试验/NCT02735460
NCT02735460已完成不适用

Single-center Usability Study of the Overground Gait and Balance Training Device Andago V2.0 in Patients With Gait Disorder After Stroke at a Center for Neurological Rehabilitation

Rehaklinik Zihlschlacht AG1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2016年3月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
15
试验地点
1
主要终点
Usability of the IMD according to the number of participants that are able to use the Andago V2.0

研究概览

简要总结

Andago V2.0 is a recently developed overground gait and balance training device. Many patients in neurorehabilitation suffer from gait disorders, most typically after stroke. Since pharmacological therapies are basically not available, neurorehabilitation plays an important role in the treatment of such patients. The Andago V2.0 may represent a useful device in the rehabilitation of stroke and other neurological patients featuring a severe gait disorder. Therefore a study has been designed to investigate the usability of the Andago V2.0 in the setting of a neurorehabilitation clinic. The primary outcomes of this study are the usability and acceptance of the investigational medical device (IMD). Usability is mainly measured by the time spent for the set-up and release of the participant, achieved training times and distances, the number of stumbles, collisions and emergency stops and the error messages during the session. Besides patient and therapist satisfaction with the Andago V2.0 is recorded.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent as documented by signature
  • Primary diagnosis of cerebral infarction (ICD-10: I63.0-I63.9) or intracerebral haemorrhage (ICD-10: I61.0-I69.9) independent of its location, age or cause
  • Gait disorder defined by a category of 1 to 3 on the Functional Ambulation Classification (FAC) (17)
  • Age above 18 years
  • Admission to Rehaklinik Zihlschlacht for in-patient neurorehabilitation

排除标准

  • Inability of the participant to understand the informed consent or to follow the procedures of the study, e.g., due to language problems, psychiatric disorders, cognitive impairment or aphasia (item 9 of the National Institute of Health Stroke Scale (NIHSS) ≥2)
  • Weight >135 kg
  • Height >200 cm
  • Bone fragility (e.g., non-consolidated fractures or osteotomies including craniotomies, osteopenia, osteoporosis or symptoms or indices in the patient history that infer a higher risk of bone density reduction)
  • Unstable arthroplasty
  • Uncontrolled knee or ankle instability that would still pose a danger despite the Body Weight Support (BWS) (especially lateral instability)
  • Lack of head control
  • Joint contractures
  • Relevant differences in leg length
  • Skin lesions (including pressure sores or enteric stomata) in areas of contact with harness support or lower extremity loading (feet)
  • Relevant sensory impairment in the lower limbs and trunk, especially with reduced pain sensation
  • Recent history or significant risk of seizures
  • Relevant cardiovascular conditions, e.g., cardiac insufficiency and thoracotomy, uncontrolled orthostatic hypotension or other circulatory problems, vascular disorders of the lower limbs
  • Mechanical ventilation
  • Long-term infusions (e.g., baclofen pump, other intrathecal pumps)
  • Any medical condition preventing active rehabilitation and/or the use of the Andago V2.0 (e.g., respiratory disease, pregnancy, orthopedic conditions, infections or inflammatory disorders, osteomyelitis)
  • Participation in another interventional study within the 30 days preceding and during the present study

研究组 & 干预措施

Treatment arm

Experimental

In this arm the Andago V2.0 is used.

干预措施: Andago V2.0 (Device)

结局指标

主要结局

Usability of the IMD according to the number of participants that are able to use the Andago V2.0

时间窗: 3 weeks

Acceptance of the IMD as measured by a therapist satisfaction questionnaire

时间窗: 3 weeks

Acceptance of the IMD as measured by a patient satisfaction questionnaire

时间窗: 3 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验